Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.084 | Facilitator-guided Acceptance and Commitment Bibliotherapy for parents of young children with neurodevelopmental disorders: A randomised controlled trial |
Dr. CHONG Yuen Yu 莊婉瑜 |
| 2023.420 | Deep-learning-powered, smartphone-delivered, Acceptance and Commitment Therapy for parents of children with special needs: A feasibility study | Prof. CHONG Yuen Yu |
| 2021.062 | Effectiveness of Prosocial-orientated Acceptance and Commitment Training (PACT) programme for parents of children with special health care needs in response to outbreaks of novel infectious disease: A randomised controlled trial |
Dr. CHONG Yuen Yu 莊婉瑜 |
| 2024.336 | Artificial intelligence-driven, chatbot-assisted acceptance and commitment therapy (Pai.ACT) for parents of young children with neurodevelopmental disorders: A randomised controlled trial | Prof Chong Yuen Yu |
| 2019.589 | Embodying a compassionate self through Acceptance and Commitment Therapy for parents and children with eczema: A family based eczema management programme |
Dr. CHONG Yuen Yu 莊婉瑜 |
| 2019.608 | Effects of Acceptance and Commitment Therapy-based asthma management training program for parents of young children with neurodevelopmental comorbidities: A randomized controlled trial |
Dr. CHONG Yuen Yu 莊婉瑜 |
| 2023.065 | The acute effect of adding whole body vibration as warm-up on the lower limb functional stability among the recreational adult athletes | Mr. CHONG Yat Hin |
| 2016.478 | Determinants on the Variability of Epworth Sleepiness Scale (ESS) in Chinese Patients with Obstructive Sleep Apnea (OSA) |
Miss CHONG Wing Chi 莊穎芝 |
| 2019.182 | Clinical application of whole genome sequencing and transcriptome sequencing technique to reveal the molecular diagnosis of undiagnosed disease |
Dr. CHONG Shuk Ching 莊淑貞 |
| 2019.293 | Metabolomics profiling study for patients with citrin deficiency |
Dr. CHONG Shuk Ching 莊淑貞 |
| 2019.464 | Retrospective study of mitochondrial disorders in Hong Kong |
Dr. CHONG Shuk Ching 莊淑貞 |
| 2019.685 | Parental attitudes on newborn genetics screening program in Hong Kong |
Prof. CHONG Shuk Ching 莊淑貞 |
| 2017.135 | Clinical classification of osteogenesis imperfecta and genotype-phenotype correlation in local Chinese patients |
Dr. CHONG Shuk Ching 莊淑貞醫生 |
| 2023.380 | Evaluation of the Hong Kong Genome Project (HKGP) | Dr. CHONG Shuk Ching |
| 2020.621 | Effectiveness of Technology-assisted Interventions in Hybrid Cardiac Rehabilitation (TecHCR) among Coronary Heart Disease Patients | Ms. CHONG Mei Sin |
| 2020.263 | Factors associating with participation and adherence of cardiac rehabilitation programme among coronary heart disease patients | Ms. CHONG Mei Sin |
| 2019.440 | Development of objective measure of psychotropic substances abuse using Automatic Retinal Image Analysis (ARIA) |
Dr. CHONG Marc Ka Chun 莊家俊 |
| 2023.622 | Projecting the impact of population aging on mortality attributable to extreme heat | Dr. CHONG Marc Ka Chun |
| 2023.528 | SAfe immunomodulation reserVEd for Mild-to-mOderate, REcent-onset TED (SAVE-MORE-TED) - a multi-center, randomized, double-masked, placebo-controlled trial | Dr. CHONG Kelvin Kam Lung |
| 2021.473 | Mapping the Thyroid Associated Orbitopathy (TAO) Genes by Whole Genome Sequencing (WGS) | Dr. CHONG Kelvin Kam Lung |
| 2023.422 | A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients with Pulmonary Fibrosis or Thyroid Eye Disease | Prof. CHONG Kelvin Kam Lung |
| 2022.199 | Deep learning and radiomics algorithm of neuroimaging for TED in Hong Kong – A territory-wide study from the HADCL |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2023.191 | Site-specific microbiome in common lacrimal gland disorders | Dr CHONG Kelvin Kam Lung |
| 2021.271 | Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress (VIEW) therapies for meibomian gland dysfunction - a multicentre, randomized, assessor-masked, active-controlled clinical trial |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2022.582 | Efficacy and tolerability of 0.2% hyaluronic acid & 2% ectoin topical eye drops, Vitamin A ointment, and lid wipe in post-COVID Meibomian Gland Dysfunction (MGD): a 3-arm randomized clinical trial |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2023.352 | Ocular surface damage and alteration in microbiome among cocaine and ice users - a prospective observational study for their health enhancement | Dr. CHONG Kelvin Kam Lung |
| 2020.349 | Early detection and surveillance of COVID-19 infection by non-invasive ophthalmic evaluations |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2019.489 | Multiparametric MRI-based radiological activity score (RAS) in Thyroid Associated Orbitopathy (TAO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.465 | Ocular microenvironment and mucosal microbiota reveal COVID-19 severity, transmissibility and model drug responses |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.097 | Efficacy and safety of Intense Pulsed Light (IPL) on dry eye associated with Thyroid Associated Orbitopathy (TAO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.478 | Hong Kong IgG4-Related Disease Registry |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2019.007 | Infrared Pupillometry and Eye-tracking as Next-generation Non-Intrusive Means to Identify Subjects Under Influence of Psychoactive Drug and Vision-related Harms |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.433 | Identification of new susceptibility and disease-causing genes in the pathogenesis and prediction of thyroid associated orbitopathy (TAO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2016.325 | Combined Radiotherapy and Intravenous Steroid for Early Progressive Thyroid Eye Disease |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.025 | 3D-printed Surgical Instruments and Orbital Models (3SIOM) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2014.530 | Prevalance and progression of open angle glaucoma and ocular hypertension in thyroid-associated orbitopathy (TAO) patients in the Hong Kong Chinese population | Dr. CHONG Kelvin Kam Lung |
| 2016.038 | Mitomycin, Intubation vs No adjuvant In MUcosal-preserving Mechanical endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction (MINIMUM endonasal DCR for PANLDO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2015.298 | Change in retinal, choroidal and nerve fiber layer thickness in thyroid associated orbitopathy |
Prof. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.151 | Registry of oculoplastic and adnexal disorders (ROAD) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.570 | IgG4-related ophthalmic disease (IgG4-ROD) in Hong Kong |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.037 | Ocular Hypertension and Glaucoma in Thyroid Associated Orbitopathy |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.327 | A randomized, double-masked, clinical trial comparing extended vs standard endonasal dacryocystorhinostomy (ExStEND) for primary acquired nasolacrimal duct obstruction |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2010.594 | Biological changes in Thyroid associated orbitopathy/Graves’ Ophthalmopathy (TAOB): Hong Kong Thyroid Eye Assessment and Management (HK-TEAM) Study | Dr. CHONG Kelvin Kam Lung |
| 2024.294 | Supporting orthoptic assessment for moderate-to-severe active Thyroid Eye Disease patients with diplopia | Dr. CHONG Kelvin Kam Lung |
| 2014.124 | Novel strategy using peripheral blood mononuclear cells (PBMC) as a rapid diagnosis for Thyroid-Associated Orbitopathy (TAO) | Dr CHONG Kelvin Kam Lung |
| 2014.129 | Validation of immunophilins FK506-binding proteins (FKBPs) and their autoantibodies in rapid diagnosis of Thyroid associated orbitopathy (TAO) disease progression | Dr. CHONG Kelvin Kam Lung |
| 2014.128 | Standard diagnostic algorithm for dysthyroid optic neuropathy – Systematic application of clinical investigational devices | Dr. CHONG Kelvin Kam Lung |
| 2014.138 | Using topical CSA to control ocular surface inflammation and improves dry eyes in patients with thyroid eye disease | Prof Chong Kelvin Kam Lung |
| 2007.467 | Moh's Micrographic Surgery (MMS) in Hong Kong for the Treatment of periocular Basal Cell Carcinoma (BCC) through a Multidisciplinary Approach | Dr Chong Kam-lung Kelvin |
| 2023.518 | A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE |
Dr. CHONG Kam Lung 莊金隆 |
Page 171 of 254.